Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02700880
Other study ID # WEARIT-III
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 2014
Est. completion date February 2019

Study information

Verified date March 2019
Source Zoll Medical Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The WEARIT-III registry enrolls subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator. The primary objective of the WEARIT-III Registry is to prospectively document the clinical course of high-risk cardiac patients with heart failure and ischemic cardiomyopathy prescribed with Wearable Cardioverter Defibrillator (WCD), such as left ventricular function recovery, arrhythmia, Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT), Left Ventricular Assist Device (LVAD), heart transplantation, and to assess the benefit of WCD in heart failure patients with ischemic cardiomyopathy.


Description:

STUDY PROCEDURE

U.S. patients prescribed a commercially available WCD (ZOLL LifeVest) will be approached by a letter from the sponsor which summarized the study purpose and procedure. Once a patient signs a consent form to participate the study, he or she will receive three questionnaire from University of Rochester, the coordination and data center for the WEARIT registry, at the time enrollment, at 3 month and 12 month follow-up, respectively. At 3 and 12-month follow-up, the physician of the patient will be contacted to provide information on arrhythmias, and interim events (ICD, CRT or LVAD implantation, heart failure episode, death), and to send us related hospital reports and echocardiogram reports to assess the improvement in left ventricular function.

STUDY DESIGN

WEARIT-III is a prospective observational patient registry. Optimal pharmacologic and/or implanted device therapy is anticipated, and the Registry physicians will not be involved in any medical care of the subjects, only collecting information on the standard care of these patients. In WEARIT-III we will also retrieve hospital records/echocardiogram reports of the subjects during follow-up using an authorization form signed by the study subjects and contact their physician to collect information on improvement of the left ventricular function whenever it is available.

DATA MANAGEMENT, DATA STORAGE

Once consented, device recordings and prescribing information will be obtained from the device provider. Data from the subject-completed questionnaire will also be obtained. Data will be entered into our web-based, password-protected clinical data-management system. That data will then be doubled-checked for accuracy by personnel working on the Registry. All study documents will be kept in a locked file room. All computers are password-protected and kept in a locked area.

DATA ANALYSIS

Routine patient clinical data as well as WCD data and clinical outcome during 1 year of follow-up will be recorded on all study patients and entered into a study-specific data- management system using our existing data management systems in the Heart Research Follow-up Program.

All analyses will be performed based on the primary and secondary objectives. Patient's clinical characteristics will be recorded and presented by descriptive statistics. Change in the clinical course will be recorded by descriptive statistics and compared to pre- WCD and post-WCD. Time-to-event analysis will be performed to assess the time until medication optimization. Clinical event will be presented as person-time rate and will be compared to previous WCD studies. Adverse events will be evaluated by raw counts and percentages. Compliance will be analyzed by mean and median of length of use and daily wear time.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date February 2019
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subjects of 18 years old or older;

2. Subjects who are recently diagnosed with heart failure of ischemic etiology (either revascularized or cannot be revascularized);

3. NYHA functional class II, III, or IVa (ambulatory);

4. Left ventricular ejection fraction = 35%;

5. Subject wearing a prescribed ZOLL LifeVest WCD;

6. Subject agrees to enter the Registry after appropriate informed consent.

Exclusion Criteria:

1. Subjects who are unable or unwilling to cooperate with the study protocol;

2. Subjects who are not willing to participate;

3. Subjects who have acute ST-segment elevation myocardial infarction (STEMI) within 30 days before prescribed with WCD;

4. Subjects with cardiomyopathy from mixed etiology;

5. Subjects with active or previously explanted cardiac devices such as ICD, CRT or LVAD except for pacemaker;

6. Subjects with a life expectancy of less than a year, including end-stage heart failure, cancer and end-stage renal disease.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
LifeVest
LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.

Locations

Country Name City State
United States University of Rochester Medical Center Rochester New York

Sponsors (2)

Lead Sponsor Collaborator
Zoll Medical Corporation University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of clinical events in heart failure patients with ischemic cardiomyopathy prescribed wearable cardioverter defibrillator (WCD) The primary objective of the WEARIT-III Registry is to prospectively document the clinical course of high-risk cardiac patients with heart failure and ischemic cardiomyopathy prescribed with WCD, such as left ventricular function recovery, arrhythmia, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy (CRT), left ventricular assist device (LVAD), heart transplantation, and to assess the benefit of WCD in heart failure patients with ischemic cardiomyopathy. 1 year
Secondary All-cause mortality Evaluate the number of deaths and the cause of death in patients with ischemic cardiomyopathy and heart failure prescribed with WCD. 1 year
Secondary Number of inappropriate shocks Evaluate the safety of WCD in patients with ischemic cardiomyopathy and heart failure measured by the frequency of inappropriate WCD shocks 1 year
Secondary WCD shock conversion success rate Evaluate WCD shock efficacy measured by shock conversion success rate among WCD appropriate shocks 1 year
Secondary NYHA functional class Evaluate the NYHA functional class of heart failure patients with ischemic cardiomyopathy at enrollment, 3-month and 1-year after the initial prescription of the WCD in WEARIT-III At enrollment, 3-month and 1-year follow-up
See also
  Status Clinical Trial Phase
Terminated NCT02240940 - PARACHUTE China Approval Trial N/A
Completed NCT00846001 - Resynchronization Surgery Combined Unified Efficacy Phase 3
Recruiting NCT05566600 - Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure Early Phase 1
Active, not recruiting NCT01961726 - Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure Phase 1/Phase 2
Terminated NCT00102128 - Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack. Phase 2
Not yet recruiting NCT03491969 - Clinical Study of Lipoic Acid on Ischemic Heart Failure Phase 4
Recruiting NCT01555320 - Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure N/A
Recruiting NCT02875639 - A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome) Phase 2
Active, not recruiting NCT01643590 - Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. Phase 2
Active, not recruiting NCT02115568 - Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203 N/A
Recruiting NCT03206593 - Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure N/A
Enrolling by invitation NCT01709279 - Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure N/A
Not yet recruiting NCT06258447 - CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction N/A